
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934**

**September 10, 2012
Date of Report (Date of earliest event reported)**

AMGEN INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
**(State or Other Jurisdiction
of Incorporation)**

000-12477
**(Commission
File Number)**

95-3540776
**(I.R.S. Employer of
Identification Number)**

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA
(Address of Principal Executive Offices)

91320-1799
(Zip Code)

805-447-1000
(Registrant's Telephone Number, Including Area Code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01. Other Events.

On September 10, 2012, Amgen Inc. (the “Company”) commenced an offering of its Senior Notes due 2019 denominated in euros (the “2019 Notes”) and Senior Notes due 2029 denominated in British pounds sterling (the “2029 Notes,” and together with the 2019 Notes, the “Notes”). Consummation of the offering is subject to market and other conditions. The Notes will be offered outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will not be registered under the Securities Act and will not be offered or sold within the United States. The final terms of the Notes will be determined at the time of pricing. The Company intends to use the net proceeds from the offering of the Notes for general corporate purposes, including the repayment of the Company’s outstanding indebtedness.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: September 10, 2012

By: /s/ JONATHAN M. PEACOCK

Name: Jonathan M. Peacock

Title: Executive Vice President and Chief Financial Officer